FrancophonIA/ELRC3.0 huggingface dataset:
English: Ensure product and solvent vial flip caps are removed and the stoppers are treated with an antiseptic solution and allowed to dry prior to opening the Mix2Vial package.
Croatian: Prije otvaranja pakiranja s uređajem Mix2Vial uklonite zatvarače lijeka i otapala te čepove obradite antiseptičkom otopinom i osušite.
English: Determine the point of injection and clean the skin with an alcohol swab.
Croatian: Odredite mjesto injiciranja i pripremite ga antiseptički.
English: • One mL Helixate NexGen 250 IU contains approximately 100 IU (250 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Helixate NexGen 250 IU nakon pripreme za primjenu sadrži približno 100 IU (250 IU / 2,5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: Helixate NexGen 1000 IU contains (1000 IU / 2.5 mL) = 400 IU octocog alfa per mL after reconstitution.
Croatian: Helixate NexGen 1000 IU sadržava (1000 IU / 2,5 ml) = 40 IU oktokoga alfa po ml nakon pripreme za primjenu.
English: • One mL Helixate NexGen 3000 IU contains approximately 600 IU (3000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Helixate NexGen 3000 IU nakon pripreme za primjenu sadrži približno 600 IU (3000 IU / 5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: • One mL Helixate NexGen 500 IU contains approximately 200 IU (500 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Helixate NexGen 500 IU nakon pripreme za primjenu sadrži približno 200 IU (500 IU / 2,5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: • One mL Helixate NexGen 1000 IU contains approximately 400 IU (1000 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Helixate NexGen 1000 IU nakon pripreme za primjenu sadrži približno 400 IU (1000 IU / 2,5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: • One mL Helixate NexGen 2000 IU contains approximately 400 IU (2000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Helixate NexGen 2000 IU nakon pripreme za primjenu sadrži približno 400 IU (2000 IU / 5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: This dose may need to be increased after one or two weeks.
Croatian: Tu dozu možda će trebati povisiti nakon jednog do dva tjedna.
English: Enyglid repaglinide
Croatian: Enyglid repaglinid
English: The recommended starting dose is 0.5 mg.
Croatian: Preporučena početna doza iznosi 0,5 mg.
English: The dose is adjusted to give the best control.
Croatian: Doza se prilagođava kako bi se postigla najbolja kontrola.
English: It is available as tablets (0.5, 1 and 2 mg).
Croatian: Dostupan je u obliku tableta (0,5, 1 i 2 mg).
English: Enyglid is taken before meals, normally up to 15 minutes before each main meal.
Croatian: Enyglid se uzima prije obroka, obično do 15 minuta prije glavnog obroka.
English: The full EPAR for Enyglid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR o lijeku Enyglid (EPAR) nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: If patients are transferred from another diabetes medicine, the recommended starting dose is 1 mg.
Croatian: Ako se bolesnici prebacuju s jednog lijeka protiv dijabetesa na drugi, preporučena početna doza iznosi 1 mg.
English: This means that Enyglid is similar to a ‘reference medicine' already authorised in the European Union (EU) called NovoNorm.
Croatian: To znači da je Enyglid sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom NovoNorm.
English: Enyglid is a ‘generic medicine'.
Croatian: Enyglid je generički lijek.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Enyglid on 14 October 2009.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Enyglid na snazi u Europskoj uniji od 14. listopada 2009.
English: For more information about treatment with Enyglid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Enyglid pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: A doctor should regularly test the patient's blood glucose to find the lowest effective dose.
Croatian: Liječnik treba redovito testirati glukozu u bolesnikovoj krvi kako bi se odredila najniža djelotvorna doza.
English: This is a summary of the European public assessment report (EPAR) for Enyglid.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Enyglid.
English: What are the benefits and risks of Enyglid?
Croatian: Koje su koristi i rizici lijeka Enyglid?
English: Enyglid is a diabetes medicine that contains the active substance repaglinide.
Croatian: Enyglid je lijek protiv dijabetesa koji sadrži djelatnu tvar repaglinid.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Enyglid.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek Enyglid da bi preporučilo njegovo odobrenje za stavljanje na tržište te uvjete za njegovu primjenu.
English: Because Enyglid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Croatian: Budući da je Enyglid generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: Other information about Enyglid
Croatian: Ostale informacije o lijeku Enyglid
English: It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) is not adequately controlled by diet, weight reduction and exercise.
Croatian: Koristi se skupa s dijetom i tjelovježbom kako bi se snizile razine glukoze (šećera) kod bolesnika čija hiperglikemija (visoke razine šećera u krvi) nije odgovarajuće kontrolirana dijetom, smanjenjem tjelesne težine i tjelovježbom.
English: The CHMP concluded that, in accordance with EU requirements, Enyglid has been shown to have comparable quality and to be bioequivalent to NovoNorm.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) zaključio je kako, u skladu sa zahtjevima EU-a, lijek Enyglid posjeduje usporedivu kvalitetu te je bioekvivalentan s lijekom NovoNorm.
English: Because Enyglid is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, NovoNorm.
Croatian: Budući da je Enyglid generički lijek, ispitivanja su na bolesnicima bila ograničena na ispitivanja za utvrđivanje je li lijek bioekvivalentan referentnom lijeku NovoNorm.
English: Enyglid helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Croatian: Enyglid pomaže da gušterača proizvodi više inzulina prilikom obroka te se koristi za kontrolu dijabetesa tipa 2.
English: Enyglid may also be used with metformin (another diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Croatian: Enyglid se također može koristiti s metforminom (drugim lijekom protiv dijabetesa) kod bolesnika s dijabetesom tipa 2 čije razine glukoze u krvi nisu zadovoljavajuće kontrolirane samim metforminom.
English: The Committee recommended that Enyglid be given marketing authorisation.
Croatian: Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Enyglid.
English: Why has Enyglid been approved?
Croatian: Zašto je lijek Enyglid odobren?
English: How is Enyglid used?
Croatian: Kako se Enyglid koristi?
English: How has Enyglid been studied?
Croatian: Kako se Enyglid ispitivao?
English: What is Enyglid used for?
Croatian: Za što se Enyglid koristi?
English: Enyglid can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Croatian: Enyglid se također može koristiti kod pacijenata s dijabetesom tipa 2 čije su razine glukoze u krvi dobro kontrolirane dijetom ali koji povremeno imaju problema s gubitkom kontrole nad glukozom u krvi.
English: Enyglid is used in adults who have type 2 diabetes.
Croatian: Enyglid se koristi za liječenje odraslih bolesnika s dijabetesom tipa 2.
English: What is Enyglid?
Croatian: Što je Enyglid?
English: Therefore, the CHMP's view was that, as for NovoNorm, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMPa kako koristi nadmašuju utvrđene rizike, kao i kod lijeka NovoNorm.
English: Revaccination is required every six months.
Croatian: Docjepljivanje je potrebno svakih šest mjeseci.
English: This will help protect them against the disease.
Croatian: To im pomaže u zaštiti od bolesti.
English: This summary was last updated in November 2018.
Croatian: Sažetak je posljednji put ažuriran u studenome 2018.
English: Sufficient justification for extrapolation of these data to other strains was provided.
Croatian: Dostavljeno je dostatno opravdanje za ekstrapolaciju tih podataka na druge sojeve.
English: These strains belong to four different serotypes (groups) of the virus known as O, A, Asia 1 and SAT2, and are selected, depending on the epidemiological need, from the following eight strains: O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir and SAT2 Saudi Arabia.
Croatian: Ti sojevi pripadaju četirima različitim serotipovima (skupinama) virusa poznatima pod nazivima O, A, Asia 1 i SAT2 i odabrani su, ovisno o epidemiološkoj potrebi, među sljedećih osam sojeva: O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir i SAT2 Saudi Arabia.
English: Further information can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/aftovaxpur-doe.
Croatian: Više informacija nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/veterinary/EPAR/aftovaxpur-doe.
English: When animals are vaccinated at 2 weeks of age, revaccination is recommended at 8 to 10 weeks.
Croatian: Kad se životinje cijepe s dva tjedna starosti, docjepljivanje se preporučuje s 8 do 10 tjedana.
English: This was considered acceptable, given the laboratory data and taking into account that vaccination against foot-and-mouth disease is currently not permitted in the EU under legal controls on foot-and-mouth disease.
Croatian: To se smatralo prihvatljivim s obzirom na laboratorijske podatke i uzimajući u obzir činjenicu da cijepljenje protiv slinavke i šapa trenutačno nije dopušteno u EU-u, u skladu sa zakonodavstvom u pogledu kontrole slinavke i šapa.
English: They usually resolve over a four-week period after vaccination but may last longer in a small number of animals.
Croatian: Obično se povlače tijekom razdoblja od četiri tjedna nakon cijepljenja, ali u malog broja životinja mogu se zadržati i duže.
English: If someone is accidentally injected with this product, they must seek medical advice immediately even if only a very small amount is injected.
Croatian: U slučaju nehotičnog ubrizgavanja ovog veterinarsko-medicinskog proizvoda osoba mora potražiti hitnu medicinsku pomoć čak ako je ubrizgana i vrlo mala količina.
English: In the future, if the animals are exposed to foot-and-mouth disease virus, the immune system will be able to produce antibodies more quickly.
Croatian: Ako životinje ubuduće budu izložene virusu slinavke i šapa, njihov će imunosni sustav brže moći proizvesti protutijela.
English: One, two or four weeks after vaccination animals were exposed to the appropriate strain of live foot-and-mouth disease virus.
Croatian: Tjedan, dva ili četiri tjedna nakon cijepljenja životinje su bile izložene odgovarajućem soju živog virusa slinavke i šapa.
English: The measure of effectiveness was the reduction in clinical signs of foot-and-mouth disease.
Croatian: Mjerilo učinkovitosti bilo je slabljenje kliničkih znakova slinavke i šapa.
English: The withdrawal period for meat and milk from cattle and sheep and for meat from pigs treated with Aftovaxpur DOE is ‘zero' days which means that there is no mandatory waiting time.
Croatian: Razdoblje karencije za meso i mlijeko goveda i ovaca liječenih VMP-om Aftovaxpur DOE iznosi „nula” dana, odnosno, nema obveznog razdoblja čekanja.
English: When it is given to cattle, pigs and sheep, the immune system recognises the virus as ‘foreign' and makes antibodies against it.
Croatian: Kada se cjepivo daje govedima, svinjama i ovcama, imunosni sustav prepoznaje virus kao „strano tijelo” i protiv njega proizvodi protutijela.
English: The range of antibodies produced following vaccination with Aftovaxpur DOE was different from that produced by natural infection; this makes it possible to distinguish vaccinated from infected animals, which is important for disease control.
Croatian: Raspon protutijela proizvedenih nakon cijepljenja VMP-om Aftovaxpur DOE bio je drugačiji od onog proizvedenog prirodnom infekcijom, što omogućava razlikovanje cijepljenih životinja od zaraženih i važno je za kontrolu bolesti.
English: Laboratory studies for the individual strains were conducted in cattle or pigs.
Croatian: Laboratorijska ispitivanja za pojedinačne sojeve provedena su na govedima ili svinjama.
English: In addition, studies in published papers were provided, which examined the effect of vaccination in cattle, sheep, and pigs.
Croatian: Osim toga, dostavljeni su objavljeni radovi o ispitivanjima u kojima se proučavao učinak cijepljenja na goveda, ovce i svinje.
English: The vaccine is given to cattle and sheep as an injection under the skin whilst for pigs the injection is given into a muscle.
Croatian: Govedima i ovcama cjepivo se daje injekcijom pod kožu, dok se svinjama injekcija daje u mišić.
English: Some studies also looked at the levels of antibodies in cattle, sheep and pigs after single and repeated doses of the vaccine.
Croatian: U nekim su ispitivanjima proučavane razine protutijela u goveda, ovaca i svinja nakon jedne doze i više ponovljenih doza cjepiva.
English: Vaccine containing O1 Manisa antigen reduces clinical signs of foot-and-mouth disease in cattle, sheep and pigs.
Croatian: Primjenom cjepiva koje sadržava antigen 01 Manisa ublažavaju se klinički znakovi slinavke i šapa u goveda, ovaca i svinja.
English: Aftovaxpur DOE is a vaccine used to vaccinate cattle, sheep and pigs from two weeks of age against foot-and-mouth disease.
Croatian: Aftovaxpur DOE je cjepivo kojim se cijepe goveda, ovce i svinje od dva tjedna starosti protiv slinavke i šapa.
English: For more information about using Aftovaxpur DOE, see the package leaflet or contact your veterinarian or pharmacist.
Croatian: Za dodatne informacije o primjeni VMP-a Aftovaxpur DOE pogledajte uputu o VMP-u, odnosno obratite se veterinaru ili ljekarniku.
English: Foot-and-mouth disease affects cloven-hoofed animals and causes fever, followed by blisters on the inside of the mouth and on the feet which may rupture and lead to lameness.
Croatian: Slinavka i šap pogađa papkare te uzrokuje vrućicu i stvaranje čireva s unutarnje strane usta i na papcima koji mogu puknuti i prouzročiti hromost.
English: Aftovaxpur DOE received a marketing authorisation valid throughout the EU on 15 July 2013.
Croatian: Za VMP Aftovaxpur DOE izdano je odobrenje za stavljanje u promet koje je na snazi u EU-u od 15. srpnja 2013.
English: The European Medicines Agency decided that Aftovaxpur DOE's benefits are greater than its risks and it be approved for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od VMP-a Aftovaxpur DOE nadmašuju s njim povezane rizike te se može izdati odobrenje za njegovu primjenu u Europskoj uniji.
English: The start of protection is 1 week after vaccination in cattle and sheep and 4 weeks after vaccination in pigs.
Croatian: U goveda i ovaca zaštita počinje tjedan dana nakon cijepljenja, a u svinja četiri tjedna nakon cijepljenja.
English: Other information about Aftovaxpur DOE
Croatian: Ostale informacije o VMP-u Aftovaxpur DOE
English: A slight increase in rectal temperature, of up to 1.2 °C for 4 days, may affect up to 1 in 10 animals following vaccination.
Croatian: U najviše jedne od deset životinja nakon cijepljenja može doći do blagog porasta rektalne temperature, do 1,2 °C tijekom četiri dana.
English: Aftovaxpur DOE contains an adjuvant (liquid paraffin) to enhance the immune response.
Croatian: Aftovaxpur DOE sadržava adjuvans (tekući parafin) kako bi se pojačala imunosna reakcija.
English: Swellings (up to 12 cm diameter in ruminants and 4 cm in pigs) at the injection site occur in most animals after vaccination.
Croatian: U većine životinja nakon cijepljenja se pojavljuju otekline (promjera do 12 cm u preživača i 4 cm u svinja) na mjestu primjene injekcije.
English: Aftovaxpur DOE is an emulsion containing liquid paraffin.
Croatian: Aftovaxpur DOE je emulzija koja sadrži tekući parafin.
English: Accidental injection of liquid paraffin may cause severe pain and swelling, particularly if injected into a joint or finger - this could result in the loss of the finger if prompt medical attention is not given.
Croatian: Slučajno ubrizgavanje tekućeg parafina može prouzročiti snažan bol i oticanje, naročito ako se ubrizga u zglob ili prst.
English: What is Aftovaxpur DOE and what is it used for?
Croatian: Što je Aftovaxpur DOE i za što se primjenjuje?
English: An overview of Aftovaxpur DOE and why it is authorised in the EU
Croatian: Pregled informacija o VMP-u Aftovaxpur DOE i zašto je odobren u EU-u
English: What are the risks associated with Aftovaxpur DOE?
Croatian: Koji su rizici povezani s VMP-om Aftovaxpur DOE?
English: The studies showed that Aftovaxpur DOE leads to adequate blood levels of antibodies against foot-andmouth disease strains following a single vaccination.
Croatian: Ispitivanja su pokazala da se primjenom VMP-a Aftovaxpur DOE u krvi postižu primjerene koncentracije protutijela protiv virusa slinavke i šapa nakon jednog cijepljenja.
English: Why is Aftovaxpur DOE authorised in the EU?
Croatian: Zašto je VMP Aftovaxpur DOE odobren u EU-u?
English: Aftovaxpur DOE is a vaccine.
Croatian: Aftovaxpur DOE je cjepivo.
English: Aftovaxpur DOE is available as a liquid emulsion for injection and can only be obtained with a prescription.
Croatian: VMP Aftovaxpur DOE dostupan je kao tekuća emulzija za injekciju i izdaje se samo na veterinarski recept.
English: Aftovaxpur DOE (Foot-and-mouth disease vaccine, killed)
Croatian: Aftovaxpur DOE (cjepivo protiv slinavke i šapa, inaktivirano)
English: Aftovaxpur DOE contains up to three strains of inactivated (killed) foot-and-mouth disease virus.
Croatian: Aftovaxpur DOE sadržava do tri soja inaktiviranog (mrtvog) virusa koji uzrokuje slinavku i šap.
English: What benefits of Aftovaxpur DOE have been shown in studies?
Croatian: Koje su koristi od VMP-a Aftovaxpur DOE utvrđene u ispitivanjima?
English: How does Aftovaxpur DOE work?
Croatian: Kako se Aftovaxpur DOE primjenjuje?
English: How is Aftovaxpur DOE used?
Croatian: Kako djeluje Aftovaxpur DOE?
English: Aftovaxpur DOE contains strains of foot-and-mouth disease virus that have been inactivated so they cannot cause the disease.
Croatian: Ti su sojevi inaktivirani tako da ne mogu prouzročiti bolest.
English: Strength Pharmaceutical Form
Croatian: Doza Farmaceutsk i oblik
English: Treatment should be continued long-term.
Croatian: Liječenje se treba nastaviti na dulje razdoblje.
English: At the start of the study patients in both groups had an average score of 10.
Croatian: Na početku ispitivanja bolesnici u obje skupine imali su prosječan rezultat 10.
English: These effects are usually mild or moderate and do not last.
Croatian: Navedene nuspojave obično su blage ili umjerene i ne traju dugo.
English: Regarding safety, although side effects related to the eye are very common, they are usually manageable.
Croatian: Kad je riječ o sigurnosti, premda su nuspojave povezane s okom veoma učestale, uglavnom ih je moguće kontrolirati.
English: The recommended dose is 1 drop in each eye 4 times a day during waking hours.
Croatian: Preporučena doza je jedna kap u svako oko 4 puta na dan u prvih nekoliko sati nakon buđenja.
English: The doctor may decrease the dose progressively to 1 drop a day depending on the results of eye examinations.
Croatian: Liječnik može postupno sniziti dozu na jednu kap na dan ovisno o rezultatima oftalmološkog pregleda.
English: This is a summary of the European public assessment report (EPAR) for Cystadrops.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Cystadrops.
English: Cystadrops contains the active substance mercaptamine (also known as cysteamine).
Croatian: Lijek Cystadrops sadrži djelatnu tvar merkaptamin (također poznata kao cisteamin).
English: Cystadrops mercaptamine
Croatian: Cystadrops merkaptamin
English: What measures are being taken to ensure the safe and effective use of Cystadrops?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Cystadrops?
English: The score ranges from 0 to 28, with 0 corresponding to no crystals.
Croatian: Rezultat se kreće u rasponu između 0 i 28, pri čemu 0 upućuje na nepostojanje kristala.
English: Because the number of patients with cystinosis is low, the disease is considered ‘rare', and Cystadrops was designated an ‘orphan medicine' (a medicine used in rare diseases) on 7 November 2008.
Croatian: Budući da je broj bolesnika s cistinozom nizak, ta se bolest smatra „rijetkom” te se Cystadrops označava kao lijek za rijetke bolesti od 7. studenoga 2008.
English: The most common side effects with Cystadrops (which may affect more than 1 in 10 people) are related to the eye and include pain, itching and irritation in the eye, increased lacrimation (watering eyes), blurred vision and ocular hyperaemia (red eye).
Croatian: Najčešće nuspojave zabilježene pri primjeni lijeka Cystadrops (koje se mogu javiti u više od 1 na 10 osoba) povezane su s okom i uključuju bol, svrbež i iritaciju oka, pojačano suzenje oka, zamagljen vid i okularnu hiperemiju (crvenilo oka).
English: The full EPAR for Cystadrops can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Cystadrops nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cystadrops's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi lijeka Cystadrops nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: The medicine also improved other symptoms of cystinosis such as photophobia.
Croatian: Primjenom lijeka također su ublaženi drugi simptomi cistinoze, kao što je fotofobija.
English: What is Cystadrops and what is it used for?
Croatian: Što je Cystadrops i za što se koristi?
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Cystadrops can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Croatian: Sažetak mišljenja Odbora za lijekove za rijetke bolesti o lijeku Cystadrops dostupan je na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Other information about Cystadrops
Croatian: Ostale informacije o lijeku Cystadrops